Pharmacogenetics: From bench science to the bedside

Drug Information Journal

Volumn 42, Issue 5, 2008, Pages 503-513

  Shih, Ted ^a   Vourvahis, Manoli ^a   Singh, Madhu ^b   Papay, Julie ^c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Individualized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ABACAVIR; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; ATOMOXETINE; AZATHIOPRINE; BIOLOGICAL MARKER; CETUXIMAB; CYTOCHROME P450; DONEPEZIL; DROTRECOGIN; DRUG METABOLITE; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; IMATINIB; IRINOTECAN; MARAVIROC; MERCAPTOPURINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RITUXIMAB; ROSIGLITAZONE; TAMOXIFEN; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; WARFARIN;

ADJUVANT THERAPY; ALZHEIMER DISEASE; BREAST CANCER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA MICROARRAY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MANUFACTURE; DRUG MARKETING; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GOVERNMENT REGULATION; HUMAN; MEDICAL INFORMATION; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; REVIEW; RISK BENEFIT ANALYSIS; RISK MANAGEMENT;

EID: 53849091014     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150804200511     Document Type: Review

References (36)

1. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57:119-137.
2. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
3. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev. 2006;58(3):521-590.
4. Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm. 2006; 63:2101-2110.
5. Weinshilboum R. Inheritance and drug response. N Engl J Med. 2003;348:529-537.
6. Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Therapeutics. 2007;32:187-195.
7. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2:E29.
8. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359:727-732.
9. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002; 359:1121-1122.
10. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics. 2004; 14:335-342.
11. Mallal S, Phillips E, Carosi G, et al. PREDICT-1: a novel randomised prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030). 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, July 22-25, 2007, Sydney. Abstract WESS101.
12. European Federation of Pharmaceutical Industries and Associations. Key messages surrounding pharmacogenetics. September 19, 2006.
13. Vectibix (panitumumab). Package insert. Thousand Oaks, CA: Amgen, September 2006.
14. Ginsberg A, Brown T, Billings P, Lai-Goldman M. Patient and provider readiness for pharmacogenomics: a user survey [abstract]. Am Soc Hum Genet. 2006.
15. Bill HR 493: To prohibit discrimination on the basis of genetic information with respect to health insurance and employment. 110th Congress. January 16, 2007.
16. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics. 2005; 15(5):365-369.
17. Mahlknecht U, Voelter-Mahlknecht S. Pharmacogenomics: questions and concerns. Curr Med Res Opin. 2005;21:1041-1047.
18. Prous Science. Lilly plans new phase III trial of Xigris. Prous Daily Essentials. February 28, 2007.
19. Targeted therapies could make Rx companies more credible, Lilly exec says. Pink Sheet. June 27, 2007. FDC Publications.
20. Constable S, Johnson MR, Pirmohamed M. Pharmacogenetics in clinical practice: considerations for testing. Expert Rev Mol Diagn. 2006;6:193-205.
21. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004;5:645-656.
22. Roses A. Pharmacogenetics in drug development: Alzheimer's disease. Abstract for presentation at 11th International Congress of Human Genetics, Brisbane, Australia, August 6-10.
23. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23:9312-9318.
24. Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst. 2005;97:412-413.
25. Corrigan OP, Williams-Jones B. Pharmacogenetics: the bioethical problem of DNA investment banking. Stud Hist Philos Biol Biomed Sci. 2006;37:550-565.
26. Roses A. Personalized medicine: elusive dream or imminent reality?: a commentary. Clin Pharmacol Therapeutics. 2007;81(6):801-805.
27. Melzer D, Detmer D, Zimmern R. Pharmacogenetics and public policy: expert views in Europe and North America. Pharmacogenomics. 2003;4: 689-691.
28. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559-581.
29. US Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels. April 7, 2008. Available at: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm.
30. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: rectal cancer. 2007 Available at: http://www.nccn.org/ professionals/physician_gls/PDF/rectal.pdf.
31. National Academy of Clinical Biochemistry. Guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Draft version 60806. 2007.
32. US Food and Drug Administration. Guidance for industry: pharmacogenetic data submissions 2005. Available at: http://www.fda.gov/cber/gdlns/ pharmdtasub.htm.
33. OncoType Dx information accessed via Genomic health website. Available at: http://www.genomichealth.com/oncotype/about/hcp.aspx.
34. MammaPrint information accessed via Agendia website. Available at: http://www.agendia.com/en/Professional/About-MammaPrint/About-MammaPrint.
35. OncoType Dx information accessed via Genomic health website. Available at http://investor.genomichealth.com/edgar.cfm.
36. Press release by the Molecular Profiling Institute, April 25, 2005. Available at http://www.eurekalert.org/pub_releases/2005-04/ ttgr-tmp042105.php.